# Objective Assessment of the Onset of RelabotulinumtoxinA in the Elevation of the Eyebrow and Its Clinical Implications

**Authors:** Carlo Di Gregorio, Ivano Iozzo, Magda Belmontesi, Andrea De Santis, Lucia Leone, Alessandro Innocenti, Philippe Picaut, Matteo Tretti‐Clementoni

PMC · DOI: 10.1111/jocd.70745 · Journal of Cosmetic Dermatology · 2026-03-02

## TL;DR

This study shows how quickly a new botulinum toxin lifts eyebrows and reduces wrinkles around the eyes in real-world settings.

## Contribution

Demonstrates the rapid onset and efficacy of RelabotulinumtoxinA in treating glabellar and lateral canthal lines using palpebral area measurements.

## Key findings

- Most of the eyebrow-lifting effect of RelabotulinumtoxinA occurs within 2 days, peaking in 24 hours.
- Patients showed a median 11.91% increase in exposed eyelid area after treatment.
- Palpebral area measurement is a precise method for assessing treatment response in periocular botulinum toxin studies.

## Abstract

The new ready‐to‐use botulinum toxins effectively treat lateral canthal lines; there is still little data on their efficacy in treating glabellar lines. The combined treatment of lateral canthal and glabellar lines allows the eyebrow to be repositioned.

To show the onset and action of RelabotulinumtoxinA on the periocular area, by measuring the variations of the area under the eyebrow in a real‐life setting.

In this real‐life, multi‐center case series, 36 patients (30 women, 6 men), aged 30–62 years, were treated with RelabotulinumtoxinA in glabellar and lateral canthal areas; patients were treated on day 0 (T0) and followed until day 30. Photos taken at T0 and at all follow‐up time points were compared in calculating the median of the palpebral surface.

All patients responded to the treatment. Most of RelabotulinumtoxinA's effect on eyebrow position (76.25%) was seen within day 2, peaking in the first 24 h. The variation rate sharply declines by day 7. Patients showed a median increase in the exposed eyelid area of +11.91% compared to T0.

In the real‐world setting, RelabotulinumtoxinA showed efficacy in treating GLs and LCLs. In the post‐intervention phases (follow‐up and potential touch‐ups), the fast onset of the ready‐to‐use product can save time. The palpebral area measurement technique, which was selected to assess objectively the response, may allow for a higher level of precision than measuring distances in the periocular range and can be helpful in this type of study.

## Full-text entities

- **Diseases:** CSM (MESH:D019042), LCL (MESH:D010509), hypertonia (MESH:D009122), depression (MESH:D003866)
- **Chemicals:** saline (MESH:D012965), acetylcholine (MESH:D000109), RelaboNT-A (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** T-T30, T-T7, T-T2

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953746/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953746/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953746/full.md

---
Source: https://tomesphere.com/paper/PMC12953746